Amgen Inc (AMGN)

[whytestocks]

News: $AMGN European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia

THOUSAND OAKS, Calif. , Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO ® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 po...

Read the whole news https://marketwirenews.com/news-releases/european-commission-approves-blincyto-xae-blinatumomab-in-patients-with-philadelphia-chromosome-negative-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukemia-7420084.html